Health Research Authority

North West - Haydock Research Ethics Committee
3rd Floor - Barlow House
4 Minshull Street
Manchester
M1 3DZ

Telephone: 0207 104 8012

Please note: This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval

11 November 2016

Dr Freddy Frost
Cystic Fibrosis Clinical Fellow
Liverpool Heart and Chest Hospital
Apartment 17
3 Rumford Place
L3 9BZ

Dear Dr Frost

Study title:	**Aztreonam for inhalation for the treatment of acute exacerbations in cystic fibrosis. An open-label, randomised, cross-over pilot study of AZLI plus intravenous Colistin versus standard dual intravenous therapy.**
REC reference:	**16/NW/0741**
Protocol number:	**AZLI2016DN001**
EudraCT number:	**2016-002832-34**
IRAS project ID:	**206907**

Thank you for your submission of 04 November 2016, responding to the Committee's request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair.

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this opinion letter. Should you wish to provide a substitute contact point, require further

information, or wish to make a request to postpone publication, please contact the REC Manager, Ms Rachel Katzenellenbogen, nrescommittee.northwest-haydock@nhs.net.

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation as revised, subject to the conditions specified below.

Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Management permission must be obtained from each host organisation prior to the start of the study at the site concerned.

Management permission should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for NHS permission for research is available in the Integrated Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.

Where a NHS organisation's role in the study is limited to identifying and referring potential participants to research sites ("participant identification centre"), guidance should be sought from the R&D office on the information it requires to give permission for this activity.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations.

Registration of Clinical Trials

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database within 6 weeks of recruitment of the first participant (for medical device studies, within the timeline determined by the current registration and publication trees).

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to contest the need for registration they should contact Catherine Blewett (catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. Guidance on where to register is provided within IRAS.

Clinical trial authorisation must be obtained from the Medicines and Healthcare products Regulatory Agency (MHRA).

The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, either confirming clinical trial authorisation or giving grounds for non-acceptance, as soon as this is available.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

Ethical review of research sites

NHS sites

The favourable opinion applies to all NHS sites listed in the application, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS sites

The Committee has not yet completed any site-specific assessment (SSA) for the non-NHS research site(s) taking part in this study. The favourable opinion does not therefore apply to any non-NHS site at present. We will write to you again as soon as an SSA application(s) has been reviewed. In the meantime no study procedures should be initiated at non-NHS sites.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document	*Version*	*Date*
Covering letter on headed paper [REC Cover Letter]		22 September 2016
Covering letter on headed paper [REC Cover Letter]		26 October 2016
GP/consultant information sheets or letters [GP Letter]	2.0	27 September 2016
Investigator's brochure / IMP Dossier [Investigator Brochure]	14	30 September 2015
IRAS Application Form [IRAS_Form_28092016]		28 September 2016
Letter from funder [Funder's letter]		17 July 2016
Letter from sponsor [Sponsor's lett]		28 September 2016
Letter from statistician [Stats letter]		22 September 2016
Other [Clarification points from researcher re. application]		27 September 2016
Other [Email confirmation of sponsor contact]		29 September 2016
Participant consent form [Consent]	2.1	20 September 2016
Participant consent form [Consent form]	2.3	21 October 2016
Participant information sheet (PIS) [Patient Information Shees V2.2]	v2.2	20 September 2016
Participant information sheet (PIS) [PIS]	v2.3	21 October 2016
Research protocol or project proposal [AZTEC-CF PROTOCOL V7.2]	7.2	28 September 2016

Summary CV for Chief Investigator (CI) [CV Professor Walshaw]		21 September 2016
Summary CV for Chief Investigator (CI) [CV FF]		
Summary CV for student [Freddy Frost]		19 September 2016
Summary CV for supervisor (student research) [Professor Winstanley]		19 September 2016
Summary CV for supervisor (student research) [Dr Fothergill]		19 September 2016
Summary of product characteristics (SmPC) [Cayston SmPC]		
Summary, synopsis or diagram (flowchart) of protocol in non technical language [Flowchart]	2.0	27 September 2016
Validated questionnaire [CFQ-R Adults]		

Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

After ethical review

Reporting requirements

The attached document *"After ethical review – guidance for researchers"* gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website:
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/

HRA Training

We are pleased to welcome researchers and R&D staff at our training days – see details at http://www.hra.nhs.uk/hra-training/

With the Committee's best wishes for the success of this project.

Yours sincerely

Dr Tim S Sprosen
Chair

Email: nrescommittee.northwest-haydock@nhs.net

Enclosures: "After ethical review – guidance for researchers"

Copy to: Mrs Gillian Hamblin, Liverpool Heart & Chest Hospital